# EDGAR Filing Document

**Accession Number:** 0000899923
**File Stem:** 0000000000-26-002062
**Filing Date:** 2026-2
**Character Count:** 2180
**Document Hash:** 1b1048c544f744e147f77f0ffabd52f8
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000000000-26-002062.hdr.sgml**: 20260401

**ACCESSION NUMBER**: 0000000000-26-002062

**CONFORMED SUBMISSION TYPE**: UPLOAD

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20260227

**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** MYRIAD GENETICS INC
- **CENTRAL INDEX KEY:** 0000899923
- **STANDARD INDUSTRIAL CLASSIFICATION:** IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 870494517
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** UPLOAD
- **SEC FILE NUMBER:** 333-293681

**BUSINESS ADDRESS:**
- **STREET 1:** 322 NORTH 2200 WEST
- **CITY:** SALT LAKE CITY
- **STATE:** UT
- **ZIP:** 84116
- **BUSINESS PHONE:** 801-584-3600

**MAIL ADDRESS:**
- **STREET 1:** 322 NORTH 2200 WEST
- **CITY:** SALT LAKE CITY
- **STATE:** UT
- **ZIP:** 84116
**PUBLIC REFERENCE ACCESSION NUMBER**: 0000899923-26-000020

## Text-Extract

```

                                                           February 27, 2026

Samraat S. Raha
President and Chief Executive Officer
Myriad Genetics, Inc.
322 North 2200 West
Salt Lake City, UT 84116

       Re: Myriad Genetics, Inc.
           Registration Statement on Form S-3
           Filed February 24, 2026
           File No. 333-293681
Dear Samraat S. Raha:

       This is to advise you that we have not reviewed and will not review your
registration
statement.

        Please refer to Rules 460 and 461 regarding requests for acceleration.
We remind you
that the company and its management are responsible for the accuracy and
adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action
by the staff.

       Please contact Chris Edwards at 202-551-6761 with any questions.

                                                           Sincerely,

                                                           Division of
Corporation Finance
                                                           Office of Life
Sciences
cc:    Daniel T. Kajunski, Esq.

```

### Attached PDF Documents

**Attachment 1:** `filename1`

_No text found in this document._